Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a blank-check company formed to pursue an acquisition in the healthcare and life sciences sector, with an emphasis on companies advancing translational medicine from research into commercial application. The vehicle filed an 8-K current report with the Securities and Exchange Commission on June 18, 2026, signaling a material development in its business combination process. TDAC operates within the broader life sciences SPAC cohort that has drawn sustained institutional attention given the sector's pipeline-driven deal flow. For full filing history, sponsor details, deal timelines, and real-time status tracking on TDAC and hundreds of other active SPACs, sign up for complete data access at SpacDesk.